Login to Your Account

Investors are Bullish on Optimer's Fidaxomicin

By Catherine Shaffer

Monday, April 4, 2011
Excitement is building in advance of an FDA advisory committee meeting on Tuesday to review fidaxomicin, an antibiotic candidate being developed by Optimer Pharmaceuticals Inc. for Clostridium difficile infection (CDI).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription